Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Completed clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 8:07 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
121350
Shown on this page
12
Current sort
Recently updated
Status scope
Completed
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Completed. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 205–216 of 121,350 matching trials with status Completed.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers

NCT06398730
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GEH200520 Injection and GEH200521 (18F) Injection, Static - PET/CT scan
Drug · Diagnostic Test
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed No phase listed Observational

Defining Endpoints in Becker Muscular Dystrophy

NCT05257473
View directory record Official record
Conditions
Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Orange, California • Aurora, Colorado • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

NCT04692688
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
Interventions
APX3330, Placebo
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed Not applicable Interventional

A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection

NCT06168669
View directory record Official record
Conditions
Colorectal Surgery, Anastomotic Leak
Interventions
xBar system
Diagnostic Test
Lead sponsor
Exero Medical Ltd.
Industry
Eligibility
22 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Orlando, Florida • Tampa, Florida • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed Phase 2 Interventional Results available

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

NCT06046443
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Bivamelagon, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed Not applicable Interventional

Treatment for Migraine and Mood

NCT05576467
View directory record Official record
Conditions
Migraine, Depressive Symptoms
Interventions
MBCT-Telephone, MBCT-Video, Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
Amanda Shallcross
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
The Bronx, New York • Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed Phase 2 Interventional Results available

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

NCT00200200
View directory record Official record
Conditions
Hepatic Metastases, Colon Cancer, Rectal Cancer
Interventions
Bevacizumab HAI plus systemic chemotherapy, HAI plus systemic chemotherapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed Not applicable Interventional Results available

Evaluation of the Asthma Management Program to Promote Activity for Students in Schools (Asthma-PASS)

NCT04576442
View directory record Official record
Conditions
Asthma in Children
Interventions
Asthma-PASS, Basic Asthma Management (AM), Child/Caregiver Education session
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
4 Years to 12 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed Not applicable Interventional

Mindfulness, Optimism, and Resilience for Perinatal Health and Empowerment Study

NCT05840900
View directory record Official record
Conditions
Postpartum Psychiatric Disorders
Interventions
Digital Mindfulness Training
Behavioral
Lead sponsor
Nina Ayala
Other
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed Phase 2 Interventional

Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study

NCT06158113
View directory record Official record
Conditions
Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus
Interventions
Baricitinib 4 milligram Oral Tablet
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

NCT05646719
View directory record Official record
Conditions
Presbyopia
Interventions
Phentolamine Opthalmic Solution 0.75%, Placebo, Low dose pilocarpine, Low dose pilocarpine vehicle
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
40 Years to 64 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Azusa, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST
Completed Phase 2 Interventional Results available

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

NCT03033303
View directory record Official record
Conditions
Neuroblastoma
Interventions
Hu3F8, GM-CSF, Isotretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 8:07 PM EST